INFLUENCE OF LONG TERM THERAPYWITH SULPHONYLUREA DERIVATIVESON THE CAPACITY OF THE HEPATIC CYP2C9ENZYME SYSTEM OF DRUG BIOTRANSFORMATIONIN DIABETIC TYPE II PATIENTS IN THE CITYOF VOLGOGRAD
- Authors: Petrov VI1, Rogova NV1, Ledyaev YM1, Serdukova DM1
-
Affiliations:
- Issue: Vol 7, No 2 (2010)
- Pages: 14-18
- Section: Articles
- URL: https://journals.eco-vector.com/1994-9480/article/view/140186
- ID: 140186
Cite item
Full Text
Abstract
It is shown that long-standing type II diabetes mellitus leads to the reduced CYP2C9 capacity. There has been
obtained strong evidence that long term administration of sulphonylurea derivatives reduces the CYP2 C9 capacity by
significantly altering pharmacokinetics of the drugs. This requires a change in their dosing regimen . Mandatory
pharmacokinetic typing of CYP2C9 activity should be recommended to improve the efficacy of pharmacotherapy for type II
diabetes mellitus, to prevent the undesirable adverse reactions when taking the drugs and to reduce the treatment cost for
this group of patients.
obtained strong evidence that long term administration of sulphonylurea derivatives reduces the CYP2 C9 capacity by
significantly altering pharmacokinetics of the drugs. This requires a change in their dosing regimen . Mandatory
pharmacokinetic typing of CYP2C9 activity should be recommended to improve the efficacy of pharmacotherapy for type II
diabetes mellitus, to prevent the undesirable adverse reactions when taking the drugs and to reduce the treatment cost for
this group of patients.
References
- Дедов И. И., Шестакова М. В . // Consilium medicum. - Т. 11, № 12. - С. 5-8.
- Бутранова О. И. Оптимизация фармакоэкономических показателей лечения сахарного диабета типа 2 с помощью ТЭС-терапии: Автореф. дис. … канд. мед. наук. - Волгоград, 2009. - 31 с.
- Кукес В. Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. - М.: Издательство «Реафарм». - 2004. - 144 с.
- Кукес В. Г., Грачев С. В., Сычев Д. А., Раменская Г. В. Метаболизм лекарственных средств. Научные основы персонализированной медицины: руководство для врачей. - М.: ГЭОТАР-Медиа, 2008. - 304 с.
- Вabaoglu M. O., Yasar U., Sandberg M., et al. // Eur J Clin Pharmacol. - 2004. - Vol. 60 (5). - P. 337-342.
- Iwakawa S., Miyashita K., Hashimoto Y., Kuroda T. // Biol. Pharm. Bull. - 2006. - № 29 (9). - P. 1983-1985.
- Lin J. H., Lu A. Y. // Pharmacological reviews. - 1997. - Vol. 49. - № 4. - P. 403-449.
- Lundbland M. S. Interindividual reaction in drug metabolism with focus on polymorphic cythocrome 450 2C9Stockholm. Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. - Repro Print AB, 2005.
- Yasar U., Forslund-Bergengren C., Tybring G., e t a l. / / C lin P h ar m a c o l T h e r. - 2 0 0 2 . - J a n . , Vol. 71(1). - P. 89-98.
Supplementary files
